Celebrating the art and science of allosteric drug discovery
At HotSpot, we are committed to building something we believe is truly distinctive, setting ourselves apart from our peers in...
Read more
Every company has a culture, either by design or default. From our inception in 2016, we wanted to create a...
Read more
The phrase ‘build it and they will come’ dates all the way back to the Old Testament, and in more...
Read more
HotSpot Therapeutics recently announced FDA clearance of our Investigational New Drug (IND) application for HST-1011, our small molecule allosteric inhibitor...
Read more
HotSpot Therapeutics recently announced a strategic collaboration with AbbVie to develop IRF5 transcription factor inhibitors for autoimmune diseases. The following…
Read more
Immunotherapy has been the holy grail in the fight against cancer for the last decade. For good reason, we’ve been...
Read more
White Hat Hackers, sometimes called “ethical hackers,” are individuals that work to find and fix security problems in a system...
Read more
It is in moments like this that we are reminded of the collective power of good to overcome the disenfranchised…
Read more
No, your next doctor will not be a robot. Nor will an algorithm cure cancer. However, AI technology will absolutely...
Read more
The pharmaceutical industry still faces unrelenting challenges across the entirety of the drug development landscape. According to Piper Sandler’s recent...
Read more
Today marks an important point in our journey to patients as HotSpot Therapeutics announces its $100MM Series C financing. This infusion of…
Read more
Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4) in 2011…
Read more
Returning to work following the pandemic presents an opportunity to think creatively about how to re-configure the workplace
Read more
Today marks an important milestone for HotSpot Therapeutics as we announce our Series B financing, but it also marks a...
Read more
DNA encoded libraries (DEL) have received a lot of attention over the past few years. They’ve been hailed as “highly...
Read more
The conventional approach to drug discovery shines a light on specific target proteins, using an arsenal of biochemical and virtual...
Read more
I was excited to participate in Allison Johnson’s recent Biocentury article reflecting on the growing interest of industry in allostery and why...
Read more
Advances in computational, biophysical and library technologies have driven the emergence of a new drug discovery paradigm with the power...
Read more
The predictions around the impact of artificial intelligence (AI) have been broad reaching but it’s clear that not everyone is...
Read more
What is a regulatory hotspot? A regulatory hotspot is a privileged allosteric site used by nature to regulate the function...
Read more
This is an exciting time for small molecule drug discovery and soon for patients, who have been underserved by current...
Read more
Lately it seems that allostery is constantly in the news, especially in stories covering a series of high-profile financings by...
Read more
Most conventional small molecule drugs engage directly with the engine of a protein’s function, aiming to often turning off an...
Read more
In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around agile organizations. This...
Read more
It starts off with flu-like symptoms and progresses to a perpetual low-grade fever, excessive sweating and loss of appetite. A...
Read more